Biocon Ltd.    
28 Sep 2020
439.80
0.43%
Axis Direct
Biocon Ltd is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immune suppressants and anti-diabetic drugs.
Biocon Ltd. is trading above it's 200 day SMA of 362.3
Biocon Ltd.    
27 Jul 2020
439.80
0.43%
Nirmal Bang Institutional
Biocon's revenue in 1QFY21 stood at Rs16,710mn, which is 8.2%/7.0% above our/consensus estimates and up 6%/14% QoQ/YoY. The beat came on the back of higher biosimilar sales and continued growth in generics business (led by higher demand for APIs across markets). Biosimilar sales during the quarter were probably led by Ogivri (biosimilar Herceptin) ramping up to mid single digit market share. Going forward, we expect the recent approval for Roche's Phesgo to pose some challenge for Herceptin biosimilar in garnering further market share. Phesgo is a fixed dose combination of Herceptin and Perjeta, which reduces infusion time from a few hours to a few minutes and also aids patient convenience. Considering the large benefits in healthcare cost...
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.
Biocon Ltd.    
27 Jul 2020
439.80
0.43%
buy
Axis Direct
Biocon reported a muted set of numbers for Q1FY21 with revenues growing at 14% on annual comparison but EBIDTA contracted by~6% and PAT by 27% on back of rising costs of Biologics business and higher R&D; spends.
default
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.
Biocon Ltd.    
25 Jul 2020
439.80
0.43%
Motilal Oswal
Capital investment and product development are on track for the Generics segment, additional We maintain our EPS estimates for FY21/FY22 and value BIOS at 30x (20% discount to its five-year avg.), arriving at TP of INR450. BIOS is well-placed to deliver a 39% earnings CAGR over FY2022, led by new launches / increased market share for existing products in the Biologics segment and superior performance from the Generics / Research Services segment. New contracts, led by Mylans efforts, would lead to better market share going BIOS is on track with regard to developing Insulin Aspart. Considering new launches and strong traction from existing products, we expect a 43% CAGR in revenue to INR40b over FY2022. An increase in the number of customers and better traction from existing customers are expected to drive a 12 13% CAGR in Research Services revenue over FY2022E. BIOS delivered 16% YoY growth in this segment, led by favorable demand for API.
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.
Biocon Ltd.    
24 Jul 2020
439.80
0.43%
buy
ICICI Securities Limited
Q1FY21 revenues grew 14% YoY to | 1671 crore (I-direct estimate: | 1651 crore) mainly due to 18.9% YoY growth in biosimilars to | 692 crore. The Generics segment grew 16.1% YoY to | 599 crore. Research services segment remained flat YoY at | 422 crore. EBITDA margins contracted 512 bps YoY to 24.7% (I-direct estimate: 22.2%) mainly due to lower gross margins and higher R&D; costs. EBITDA declined 5.5% YoY to | 413 crore against I-direct estimate of | 366 crore. Adjusted PAT declined 27.6% YoY to | 149 crore (I-direct estimate: | 127 crore). Delta vis--vis EBITDA was due...
Biocon Ltd. has gained 69.51% in the last 1 Year
Biocon Ltd.    
12 Jun 2020
439.80
0.43%
Motilal Oswal
Insulin Glargine (Semglee) is Biocon-Mylans third biosimilar to be approved by the USFDA in a span of 24 months. Considering two competitors (Innovator- Sanofi; Biosimilar by Eli Lilly/Boehringer Ingelheim team; EL/BI) are already in the market and Biocon-Mylan are the third to get USFDA approval with other peers still under clinical phase, we expect Biocon (BIOS) to garner USD130m on an annualized basis from this opportunity, post commercialization in 2HFY21. BIOS recently received the USFDAs approval for its Insulin Glargine (biosimilar version Semglee) for both versions (vial and pen). Further, BIOS-Mylan has recently won a favorable ruling from the US Patent and Trial Board (USPTAB) in the patent litigation against Sanofi for 4 device patents for Lantus SoloSTAR. Moreover, in Mar20, the US district Court of New Jersey ruled that Sanofis 844 patent (product patent) was not infringed by Mylans Insulin Glargine product.
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.
Biocon Ltd.    
26 May 2020
439.80
0.43%
buy
Axis Direct
We recommend a BUY on Biocon with a Target Price of Rs 385, an upside of ~10% from CMP of Rs. 350 and Stop Loss Rs 332.
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.
Biocon Ltd.    
21 May 2020, 12:00AM
439.80
0.43%
buy
Geojit BNP Paribas
The company's medium-term growth outlook remains intact on new product launches and strong pipeline despite challenges amidst COVID19 pandemic. Therefore, we upgrade our rating to BUY on the stock with a revised target price of Rs. 390 based on 31x FY22E adj. EPS. Growth in topline despite Corona-led lockdowns Biocon recorded revenue growth of 3.4% YoY to Rs. 1,581cr, primarily driven by Small molecule segment (+14.6% to Rs. 541cr) on strong growth in generic formulation and steady increase in API sales. Research services business also grew 13.7% YoY to Rs. 607cr backed by robust growth in discovery services and development services. This...
default
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.
Biocon Ltd.    
18 May 2020
439.80
0.43%
Nirmal Bang Institutional
55%/53%, respectively. A 40% QoQ decline in the biosimilar sales led to the underperformance. The decline has been attributed to delayed shipments due ot COVID-19 Target Price: Rs272 lockdown and lower primary sales. We also estimate that 3QFY20 may also have had the benefit of tender sales in the emerging markets and hence may have been on a high base. In Downside: 17% 1QFY21, the company expects revival in biosimilar sales to 3QFY20 levels. While there are...
Biocon Ltd. has an average target of 370.80 from 6 brokers.
Biocon Ltd.    
18 May 2020
439.80
0.43%
buy
Axis Direct
Biocon reported a tepid performance for Q4FY20 mainly on account of the one-off impact of the lockdown on the sales of Biologics (including Small Molecules) business; Biologics reported YoY de-growth of ~3% at Rs. 898 cr.
Number of FIIs/FPIs holding stock rose by 216 to 445 in Jun 2020 qtr.